glp-1 agonists and sglt2 inhibitors 3. Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD SGLT2 Inhibitors and GLP-1 Receptor

Regulators protecting patients in the news The FDA issued a warning letter to an Australian facility for serious CGMP violations

There is a higher prevalence of type 2 diabetes mellitus (DT2) in patients with PsO than in the general population.25 In addition, insulin resistance induces dyslipidemia and contributes to the development of nonalcoholic hepatic steatosis (NAHS).26 Cardiovascular risk (CVR) is increased in patients with obesity and PsO who present psoriatic arthritis, and who often have other risk factors.27 The guidelines for the European Cardiology Society state that the body mass index (BMI) should not exceed 25kg/m2,28 and so early interventions to manage obesity or excess weight associated with PsO could contribute to preventing CVR

By systematically varying UV-A irradiation time, six distinct samples labeled PRGO-X were prepared, where X represented the irradiation duration of 0, 2, 4, 6, 8, and 10 h

Choose a sunscreen with SPF 30 or higher to protect against UVA and UVB rays

The combination of niacinamide and glutathione can enhance the overall health and radiance of the skin